Subjects received topical penciclovir for 4 days during successive episodes of recurrent herpes labialis. Isolation of herpes simplex virus (HSV) was attempted from lesions obtained before initiation of treatment and on each day of therapy. Isolates remained sensitive to penciclovir when tested by a plaque reduction assay, and there was no significant change in sensitivity during any treatment course or between successive treatments. The proportion of nucleoside-resistant variants present within a subset of these isolates was further investigated using a moresensitive plating efficiency assay. Although the proportion of antiviral-resistant HSV variants increased on successive days, it invariably remained a minor subpopulation. Moreover, isolates from successive episodes obtained before treatment showed no change in the proportion of resistant HSV variants. We conclude that antiviralresistant variants, which are readily detected in HSV isolates from peripheral lesions, do not accumulate in the sensory ganglia of immunocompetent patients receiving multiple courses of nucleoside analogues.
available over-the-counter in 130 countries. Surveys of virus isolates have not detected an increase in the prevalence of HSV variants resistant to nucleoside analogues [1 -3] . However, these surveys did not include patients receiving successive courses of therapy, and it may take repeated exposure to antivirals to generate resistance.
The present study assessed the antiviral susceptibility of sequential isolates from multiple successive outbreaks of recurrent herpes labialis (RHL) treated with topical penciclovir (PCV). The primary objective was to compare the antiviral susceptibility of the isolates obtained before treatment ("pretreatment isolates") with subsequent ones, including the final isolate obtained during the last episode of RHL ("final duringtreatment isolate"). In addition, because virus isolates are known to be heterogeneous mixtures of susceptible and resistant variants [4] and because the plaque reduc- tion assay (PRA) typically used for antiviral susceptibility is not designed to detect small numbers of variants, we used a plating efficiency assay (PEA) to determine whether the proportion of antiviral-resistant variants in clinical isolates increased during successive days of therapy and with successive courses of therapy.
MATERIALS AND METHODS

Clinical design.
This was an open-label, single arm, dualcenter treatment study conducted from December 1998 through June 1999. Healthy subjects, aged у18 years, had a history of at least 4 episodes of RHL per year. At each clinically confirmed recurrence, a tube of PCV cream (1%) was dispensed, and a swab was obtained for virus isolation ("day 0 swab"). Subjects applied PCV cream to lesions every 2 h during waking hours for 4 days. Subjects returned to the clinic for the following 3 days for virus isolation or cultured their lesions at home. At the end of each RHL episode, patients returned unused medication. Virus isolation. Swabs from papules, vesicle bases, or ulcers were collected into M4-RT transport medium (Micro Test) and inoculated into cultures of human embryonic lung fibroblasts (HELF) or Vero cells. HSV isolates were typed with specific monoclonal antibodies (Diagnostic Products).
PRA. PRA for antiviral susceptibility to PCV was performed as described elsewhere [5] . Medical Research Council-5 or HELF cell monolayers in 12-well plates were inoculated with virus diluted to yield 50 plaques/well and were treated in duplicate with PCV (final concentrations, 0.05-12.0 mg/mL) in an agarose overlay. After 2 days of incubation, monolayers were fixed and stained with crystal violet, plaques were counted, and the antiviral IC 50 was determined by use of linear regression.
PEA. The proportion of acyclovir (ACV)-resistant (ACV R ) HSV within an isolate was measured as described elsewhere [4] . ACV was used to detect nucleoside-resistant variants, because this assay was validated in our laboratory, because PCV and ACV are structurally related and share a similar mechanism of action, and because resistant mutants are generally cross-resistant. Of importance, similar results were achieved in a previous study of clinical isolates, regardless of whether PCV or ACV was used to detect resistance [6] . In brief, isolates were titrated on Vero cell monolayers in 10-fold dilutions. The inoculum was removed 1 h later, and an agarose overlay was added with or without ACV at 5 mg/mL. Monolayers were incubated for 10 or 4 days, respectively, and then fixed and stained with crystal violet. Plaques were counted, and the proportion of ACV R HSV was calculated as follows: mean virus titer in the wells with virus ACV/mean titer in the wells without ACV.
RESULTS
Of 150 subjects enrolled, 110 were swabbed at least once and used at least one dose of study medication. Most subjects were women (81%) and white (91%); their mean age was 36 years. Antiviral medication had been used previously for RHL by 46% of subjects. HSV was isolated from 95 subjects; 40% of swabs (424/1062) were positive. Isolation rates decreased with each successive day of the episode. For swabs collected on days 0, 1, 2 and 3, isolation rates were 73%, 48%, 24%, and 10%, respectively. IC 50 values were determined for 360 isolates, including all pretreatment and final during-treatment isolates. No PCV-resistant (PCV R ) isolates were detected (prevalence of resistance, !0.3%), including 155 obtained during therapy.
The primary objective of this trial was to compare the antiviral susceptibility of the first pretreatment isolate obtained at entry to the study with the final during-treatment isolate from the last episode of RHL. There was no significant change in antiviral susceptibility of isolates from the 14 subjects with 4 episodes of RHL that were available for this per-protocol analysis (table 1). The mean (SD) change in IC 50 was Ϫ0.08 ). Similar P p .497 findings were noted for a modified per-protocol analysis (paired isolates from 35 subjects who were culture positive by the first pretreatment swab collected in the study and by during-treatment isolates from the second, third, or fourth episode) and an intention-to-treat analysis (73 subjects from whom at least 2 isolates were obtained: 1 before treatment [day 0] and 1 subsequent isolate obtained during the same treatment period [the final during-treatment isolate]). Comparisons of withinepisode changes (mean during-treatment pretreat-IC Ϫ mean 50 ment IC 50 , by day of treatment) for the first 5 episodes and for all 3 analysis populations failed to reveal any alterations in antiviral susceptibility. The data for day-to-day changes in the intention to treat population did not show significant changes in the mean IC 50 (table 2) . Likewise, changes were not noted for the comparisons between pretreatment and final duringtreatment isolates within the first 5 episodes (table 3) or between the pretreatment isolates from episode 1 and the final during-treatment isolate obtained from episodes 1 through 5 (table 4) .
To investigate any change in the proportion of ACV R HSV variants over time, isolates from 15 randomly chosen subjects from whom an adequate isolate sample was obtained on day 0, along with subsequent during-treatment isolates from the same episode, were tested by the PEA. The proportion of ACV R HSV variants present on day 0 varied widely, but generally was in the range of 10 Ϫ4 -10 Ϫ5 . This proportion tended to increase over time within an episode (figure 1), although it is not known whether there was any corresponding change in the absolute titers of resistant variants present in these isolates. The mean increase was 3.2-fold after treatment for 1 day (13-fold for 4 of 13 episode-pairs), 7.3-fold after 2 days (13-fold for 7 of 9 episode-pairs and 16-fold for 5 of 9 isolates), and 18.4-fold after 3 days (16-fold for 6 of 7 pairs). The mean proportion of ACV R HSV variants in pretreatment isolates from the first episode ( ) was similar to that for the second Ϫ3 2.7 ϫ 10 ( ) or third ( ) episodes (there was no sta-
Ϫ3 Ϫ3
5.3 ϫ 10 1.9 ϫ 10 tistically significant increase in the proportion of ACV R HSV variants) (table 5). Finally, there was no significant correlation between IC 50 values and the proportion of resistant variants in the 21 isolates for which both measurements were done ( , simple regression). P p .82
DISCUSSION
Frequent application of topical PCV to multiple sequential episodes of RHL did not lead to selection of PCV R HSV strains, as assessed by PRA. The prevalence of resistant variants in this study was !0.3%, similar to isolates from untreated RHL episodes [1, 3] . Furthermore, comparisons of paired isolates revealed no significant change in susceptibility to PCV between the first pretreatment and final during-treatment isolates. Within-and between-episode changes in IC 50 for paired pretreatment and final during-treatment isolates were invariably small, and there was no decline in susceptibility as a function of frequency and duration of treatment. This is in agreement with the conclusions from 6 clinical trials (1446 HSV isolates from 912 patients) in immunocompetent patients treated with topical PCV or oral famciclovir (the prodrug of PCV) [7] and is consistent with a comparison of first and last isolates from subjects receiving long-term oral suppressive therapy with ACV or famciclovir [8] and with a comparison of 358 paired isolates from studies of topical PCV therapy of herpes labialis [9] . The present study differs from those others in that it demonstrates The proportion of ACV-resistant herpes simplex virus on the day indicated was determined by plating efficiency assay, as described in Materials and Methods. Each dot represents a sample available on the day indicated for which there is a paired sample from day 0. Bar, mean proportion for the day indicated. , day P p .013 0 vs. day 1;
, day 2 vs. day 0; and , day 3 vs. day 0 (un-
that multiple courses of topical therapy do not alter antiviral susceptibility.
The PRA, which correlates with clinical outcome and is widely used to monitor antiviral resistance, typically detects ACV R HSV strains when 130% of virions in an isolate are ACV R [4] . Previous work has shown that, within sensitive HSV-1 isolates, ∼10
Ϫ3
-10
Ϫ4
of the virions present are resistant [4, 10] , reflecting natural variability. In the present study, nucleoside-resistant variants were detected by PEA in the presence of high levels of ACV. Although this test was applied to isolates that had been grown in cell culture, we knew that the proportion of resistant mutants does not change significantly between the clinical specimen and the isolate derived in the laboratory [4] . PEA results indicated an increase in the proportion of ACV R HSV strains in isolates obtained during successive days of antiviral treatment, probably reflecting the selective pressure of PCV therapy. However, it is not known how treatment affected the absolute titers of resistant and sensitive virus in these isolates.
In immunocompetent patients treated with antivirals, the increase in the proportion of resistant virus does not pose a problem, since HSV is removed by immune mechanisms, regardless of antiviral susceptibility, resulting in rapid decline of HSV titer in skin lesions [11] . This was observed in the present study by the reduction in HSV with increasing duration of therapy. Thus, there are two reasons why the risk of transmission of resistant HSV from patients treated with antivirals might not increase in parallel with the increase in proportion of mutants: first, resistant virus accounts for a very small proportion of the total HSV population, as demonstrated by the lack of change in the IC 50 value; and second, the titer of HSV decreases rapidly with each day after the onset of an episode in the absence of treatment and clearance is further accelerated by treatment. Therefore, the absolute number of antiviral-resistant mutants within a lesion is decreasing rapidly each day. An additional factor may be the inability of most nucleoside-resistant HSV to establish latency in sensory ganglia [1, 12] .
The possibility of accumulation of mutants was addressed by measuring the proportions present in isolates obtained during multiple courses of treatment. The proportion of mutants in the first pretreatment isolates from successive episodes of RJL did not increase between episodes. This is consistent with the experiment of Hasegawa et al. [13] , who found that the IC 50 values of HSV isolates from 5 patients did not change while receiving 2-4 courses of oral ACV, and with findings in experimental models of genital HSV in mice [14] and guinea pigs [15] , where the presence of an adequate immune response from a primary HSV infection prevented HSV from a subsequent cutaneous reinfection from reaching the sensory ganglia or spinal cord. Among immunocompromised patients, there is a higher prevalence of ACV R HSV isolates, and clinical resistance is more common than in immunocompetent hosts [1] . This result is likely explained by a more marked accumulation and longer persistence of resistant HSV variants caused by impaired local immune clearing mechanisms. These patients also lack the immune mechanisms demonstrated in animals that prevent retrograde spread of resistant HSV from lesions to ganglia [14, 15] .
It appears that the burden of latent HSV in ganglia in an immunocompetent individual is determined by primary infection and that virus reactivating during an episode of RHL is not influenced by previous recurrences. Thus, in spite of the ease with which nucleoside-resistant HSV variants can be detected in small numbers within clinical isolates, we find that their accumulation does not occur. This is consistent with the observation that clinical resistance is rare and explains why it has not become a significant problem after extensive use of nucleoside analogues.
